Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Kobe0065
Cat. No.:
OB0225LY-0051
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and LC-MS.
Size:
Product Overview
Description:
Kobe0065 is a chemical small molecule commonly used in biomedical research exhibits potent activity and competitively inhibits the binding of H-Ras GTP to c-Raf-1 RBD.
Synonym:
436133-68-5; Kobe-0065; N-(3-Chloro-4-methylphenyl)-2-[2,6-dinitro-4-(trifluoromethyl)phenyl]-hydrazinecarbothioamide; 1-(3-Chloro-4-methylphenyl)-3-[2,6-dinitro-4-(trifluoromethyl)anilino]thiourea; N-(3-Chloro-4-methylphenyl)-2-[2,6-dinitro-4-(trifluoromethyl)phenyl]hydrazinecarbothioamide; Kobe 0065
CAS No.:
436133-68-5
Compound CID:
3827663
Formula:
C15H11ClF3N5O4S
Formula Weight:
449.79
Specification
Relative Density:
1.653 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Kobe0065 can be used for structure-based drug design (SBDD).
Library Information
Targets:
GTPase superfamily
Receptors:
Ras; Ras-Raf
Pathways:
GPCR/G protein; Apoptosis; MAPK
Plate Number:
AOCL-1
Plate Location:
f3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
20 mg/ml
Ethanol Max Solubility:
4.5 mg/mL; 10 mM
